Population
Molecular models/proteins (lipoprotein lipase [LPL], ANGPTL4, and endothelial membrane protein GPIHBP1)
Comparison
ANGPTL4 and its common polymorphic variant vs Absence of GPIHBP1 or wild-type ANGPTL4
Design
Preclinical
Authors
Loading...
May inform ANGPTL4-targeted triglyceride therapies; leaves open human translation and cardiovascular outcomes.
Elucidates the molecular basis for LPL regulation by ANGPTL4 and GPIHBP1, explaining the mechanism by which a clinically relevant ANGPTL4 variant lowers plasma triglycerides.
Mysling et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: